肝癌管理格局中的研究设计:临床试验与临床实践
本文为综述,围绕肝细胞癌(HCC)管理,概述随机对照试验与观察性研究等不同研究设计的优势与局限,讨论真实世界数据与真实世界证据的利用挑战,以回应HCC研究中尚未完全解决的问题。
要点
- 随机对照试验是肿瘤领域证据生成的金标准,可无偏估计疗效。
- 大型前瞻性观察性真实世界研究可发现罕见或长期不良事件。
- 如何利用真实世界数据与证据仍是待解决的挑战。
核心结论
- 随机对照试验是证据生成的金标准,观察性研究存在内部与外部效度问题,但设计良好的大型前瞻性真实世界研究可补充检测罕见或长期不良事件。
研究设计与样本
- 综述类文章,检索范围与纳入文献数量原文未报告;聚焦HCC研究中随机对照试验与观察性研究的比较。
主要发现
- HCC是全球第四大癌症死亡原因,预后异质性与肿瘤负荷及基础慢性肝病严重程度相关。
- HCC系统治疗的进展增加了患者管理的复杂性。
- 观察性研究存在多种可能降低内部与外部效度的问题,但大型前瞻性观察性真实世界研究可检测罕见不良事件或监测长期不良事件。
临床怎么用
- 临床解读HCC治疗证据时应区分随机对照试验与观察性研究的证据强度,并合理利用真实世界数据补充长期安全性信息。
局限性
- 本文为综述,未报告系统检索策略、纳入文献数量及定量汇总结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide and its prognosis is highly heterogeneous, being related not only to tumour burden but also to the severity of underlying chronic liver disease. Moreover, advances in systemic therapies for HCC have increased the complexity of patient management. Randomised-controlled trials represent the gold standard for evidence generation across all areas of medicine and especially in the oncology field, as they allow for unbiased estimates of treatment effect without confounders. Observational studies have many problems that could reduce their internal and external validity. However, large prospective (well-conducted) observational real-world studies can detect rare adverse events or monitor the occurrence of long-term adverse events. How best to harness real world data, which refers to data generated from the routine care of patients, and real-world 'evidence', which is the evidence generated from real-world data, represents an open challenge. In this review article, we aim to provide an overview of the benefits and limitations of different study designs, particularly focusing on randomised-controlled trials and observational studies, to address important and not fully resolved questions in HCC research.
引用
- Cabibbo G, Celsa C, Rimassa L, et al. Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. J Hepatol. 2024. PMID: 38307346. doi:10.1016/j.jhep.2024.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。